stockrowQIAGEN N.V.
QGEN Healthcare Diagnostics & Research
QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024.
- Revenue
- +0.28%
- EPS
- +7.94%
- Free cash flow
- +30.5%
- Total debt
- +13.8%
Quarter to June 2026, against a year earlier
Follow QGEN
Alert me
QIAGEN N.V. (QGEN) Net margin
QIAGEN N.V.'s net margin over the twelve months to 30 June 2026 was 19.5%, down 0.8 percentage points from fiscal 2025 (20.3%). Over the past ten years it has ranged from −2.72% (fiscal 2019) to 22.8% (fiscal 2021); the current reading is higher than 91% of that period. That is above the Diagnostics & Research industry median of −4.10% and above the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | 20.3% | 16.10 |
| FY2024 | 4.23% | (13.14) |
| FY2023 | 17.4% | (2.39) |
| FY2022 | 19.8% | (3.01) |
| FY2021 | 22.8% | 3.57 |
| FY2020 | 19.2% | 21.92 |
| FY2019 | −2.72% | (15.40) |
| FY2018 | 12.7% | 9.83 |
| FY2017 | 2.85% | (3.16) |
| FY2016 | 6.01% | (4.15) |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | 19.3% | 5.51 |
| Mar 2026 | 13.8% | (6.13) |
| Dec 2025 | 20.0% | (4.47) |
| Sep 2025 | 24.4% | 6.38 |
| 42 more quarters | Free account |
Against its own ten years
Net margin against peers
| Company | Net margin |
|---|---|
| QGEN QIAGEN N.V. | 19.5% |
| MEDP Medpace Holdings, Inc. compare | 18.2% |
| BLLN BillionToOne, Inc. compare | 11.2% |
| RVTY Revvity Inc. compare | 8.61% |
| ICLR ICON PLC compare | 5.45% |
| CRL Charles River Laboratories International, Inc. compare | 1.01% |
| RDNT RadNet, Inc. compare | −0.93% |
| GH Guardant Health, Inc. compare | −37.9% |
| GRAL GRAIL, Inc. compare | −243.8% |
| Diagnostics & Research industry median | −4.10% |
| Healthcare sector median | 0.00% |
| Market median | 1.06% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on QGEN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement